Eiger BioPharmaceuticals Discontinues Development of Ubenimex in PAH After Disappointing Results
News, Pulmonary Hypertension
Eiger BioPharmaceuticals will discontinue the development of ubenimex as a therapy for pulmonary arterial hypertension (PAH) due to disappointing results in the Phase 2 LIBERTY clinical trial. The treatment failed to ... Read more